NATCO Pharma LimitedNSE: NATCOPHARM

Press Release Apr 26 2021

· Issued by NATCO Pharma Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

The company is seeking approval from the Central Drugs Standard Control Organization for a Phase-III clinical trial of the drug. NATCO believes that the drug could be approved for compassionate use, allowing access for patients with life-threatening conditions. If approved, NATCO is prepared to launch the product within the month.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

NATCO Pharma Limited on 6ix

Earlier from NATCO Pharma

Later from NATCO Pharma

All NATCO Pharma news releases